Policosanol for managing human immunodeficiency virus-related dyslipidemia in a medically underserved population: A randomized, controlled clinical trial

Alternative Therapies in Health and Medicine

Volumn 17, Issue 2, 2011, Pages 30-35

  Swanson, Barbara ^a   Keithley, Joyce K ^a   Sha, Beverly E ^b   Fogg, Louis ^a   Nerad, Judith ^c   Novak, Richard M ^d   Adeyemi, Oluwatoyin ^c   Spear, Gregory T ^b  

^a RUSH UNIVERSITY COLLEGE OF NURSING   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c Bureau of Health Services of Cook County   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ALCOHOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIA; FEMALE; HEALTH CARE PLANNING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

ADULT; ANTICHOLESTEREMIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FATTY ALCOHOLS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICALLY UNDERSERVED AREA; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TRIGLYCERIDES;

EID: 80051948404     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outnatient Study Investigators. N Engl J Med. 1998;338(13):853-860.
2. Fontas E, van Leth F, Sabin CA, et al; DAD Study Group. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004:189(6):1056-1074.
3. Friis-Moller N, Weber R, Reiss P, et al; DAD Study Group. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17(8):1179-1193.
4. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000;23(1):35-43.
5. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289(22):2978-2982.
6. El-Sadr WM, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral naive cohort. HIV Med. 2005;6(2):1-7.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
8. Coll B, Parra S, Alonso-Villaverde C, et al. The role of immunity and inflammation in the progression of atherosclerosis in patients with HIV infection. Stroke. 2007;38(9):2477-2484.
9. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004;109(13):1603-1608.
10. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506-2512.
11. Smith C, DAD Study Group. Association between modifiable and non-modifiable risk factors and specific causes of death in the HAART era: The Data Collection on Adverse Events of Anti-HIV Drug Study. Paper presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal, Canada. Abstract 145.
12. Mocroft A, Reiss P, Gasiorowski J, et al; EuroSIDA Study Group. Serious fatal and non-fatal non-AIDS-defining illnesses in Europe. Paper presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal, Canada. Abstract 707.
13. McCarty MF. Iatrogenic lipodystrophy in HIV patients-the need for very-low-fat diets. Med Hypotheses. 2003;61(5-6):561-566.
14. Barrios A, Blanco F, Garcia-Benayas T, et al. Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. AIDS. 2002;16(15):2079-2081.
15. Ray GM. Antiretroviral and statin drug-drug interactions. Cardiol Rev. 2009;17(1):44-47.
16. Narayan S, Hawley N, Giguère P, Badley AD. Attentuated T-lymphocyte response to HIV therapy in individuals receiving HMG-CoA reductase inhibitors. HIV Clin Trials. 2003;4(3):164-169.
17. Rodriguez B, Valdez H, Mijch A, et al. Statins blunt HAART-induced CD4+ T-cell gains but have no long-term effect on virologic response to HAART. J Int Assoc Physicians AIDS Care (ChicIll). 2007;6(3):198-202.
18. Wohl DA, Tien HC, Busby M, et al. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis. 2005;41(10):1498-1504.
19. Gerber JG, Kitch DW, Fichtenbaum CJ, et al. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr. 2008;47(4):459-466.
20. Keithley J., Swanson B, Sha BE, Zeller JM, Kessler HA, Smith KY. A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia. Nutrition. 2002;18(2):201-204.
21. Chen JT, Wesley R, Shamburek RD, Pucino F, Csako G. Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy. 2005;25(2):171-183.
22. McGowan MP, Proulx S. Nutritional supplements and serum lipids: does anything work? Curr Atheroscler Rep. 2009;11(6):470-476.
23. Menendez R, Amor AM, Rodeiro I, et al. Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts. Arch Med Res. 2001;32(1):8-12.
24. Menéndez R, Arruzazabala L, Más R, et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolemia induced by a wheat starch-casein diet. Br J Nutr. 1997;77(6):923-932.
25. Menéndez R, Más R, Amor AM, et al. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol. 2000;50(3):255-262.
26. Kassis AN, Kubow S, Jones PJ. Sugar cane policosanols do not reduce LDL oxidation in hypercholesterolemic individuals. Lipids. 2009;44(5):391-396.
27. Gouni-Berthold I, Berthold HK. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J. 2002;143(2):356-365.
28. Kassis AN, Jones PJ. Lack of cholesterol-lowering efficacy of Cuban sugar cane policosanols in hypercholesterolemic people. Am J Clin Nutr. 2006;84(5):1003-1008.
29. Berthold HK, Unverdorben S, Degenhardt R, Bulitta M, Gouni-Berthold I. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA. 2006;295(19):2262-2269.
30. Francini-Pesenti F, Beltramolli D, Dall'acqua S, Brocadello F. Effect of sugar cane policosanol on lipid profile in primary hypercholesterolemia. Phytother Res. 2008;22(3):318-322.
31. Pons P, Rodriguez M, Robaina C, et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. Int J Clin Pharmacol Res. 1994;14(1):27-33.
32. Hernández F, Illnait J, Más R, et al. Effects of policosanol on serum lipids and lipoproteins in healthy volunteers. Curr Ther Res. 1992;51:568-575.
33. Aneiros E, Más R, Calderon B, et al. Effect of policosanol in lowering cholesterol levels in patients with type II hypercholesterolemia. Curr Ther Res. 1995;56(2):176-182.
34. Castaño G, Más R, Fernandez L, et al. Effects of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol. 2000;14(3):187-195.
35. Crespo N, Illnait J, Más R, Fernández L, Fernandez J, Castaño G. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus. Int J Clin Pharmacol Res. 1999;19(4):117-127.
36. Más R, Castaño G, Illnait J, et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther. 1999;65(4):439-447.
37. Castaño G, Más R, Fernández L, et al. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolemia. Drugs Aging. 2003;20(2):153-163.
38. Ortensi G, Julio G, Hector V, Pedro AT. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res. 1997;58:819-828.
39. Castaño G, Más R, Arruzazabala ML, et al. Effects of policosanol and pravastatin on lipid profile, platelet aggregation, and endothelemia in older hypercholesterolemic patients. Int J Clin Pharmacol Res. 1999;19(4):105-116.
40. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106(25):3143-3421.
41. Rubin DB. Multiple Imputations for Nonresponses in Surveys. New York, NY: John Wiley & Sons; 1987.
42. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
43. Swanson B, Keithley J. Policosanol to manage dyslipidemia in older adults. In: Watson RR, ed. Complementary and Alternative Therapies and the Aging Population: An Evidence-Based Approach. San Diego, CA; Academic Press; 2009:117-134.
44. Singh DK, Porter TD. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. J Pharmacol Exp Ther. 2006;318(3):1020-1026.
45. Nikitin Iu P, Slepchenko NV, Gratsianskii NA, et al. Results of the multicenter controlled study of the hypolipidemic drug policosanol in Russia [article in Russian]. Ter Arkhiv. 2000;72(12):7-10.
46. Prat H, Roman O, Pino E. Comparative effects of policosanol and two HMG-GoA reductase inhibitors on type II hypercholesterolemia [article in Spanish]. Rev Med Chil. 1999;127(3):286-294.
47. Cubeddu LX, Cubeddu RJ, Heimowitz T, Restrepo B, Lamas GA, Weinberg GB. Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial. Am Heart J. 2006;152(5):982.e1-982.e5.
48. Dulin MF, Hatcher LF, Sasser HC, Barringer TA. Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial. Am J Clin Nutr. 2006;84(6):1543-1548.
49. Greyling A, De Witt C, Oosthuizen W, Jerling JC. Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects. Br J Nutr. 2006;95(5):968-975.
50. Product Review: Review of Cholesterol-Lowering Supplements (Plant Sterols and Policosanol). Available at: https://www.consumerlab.com/reviews/Cholesterol-Lowering_Supplements_Review_Sterols_Policosanol/cholesterol/. Accessed January 14, 2011.